Related Experiment Video
Updated: May 29, 2026
09:02
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells
Anna Alhaddad1, Marie-Pierre Adam, Jacques Botsoa
1Université Paris-Sud, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, F-91405 Orsay, France.
Small (Weinheim an Der Bergstrasse, Germany)
|September 14, 2011
Summary
Diamond nanoparticles effectively deliver siRNA to Ewing sarcoma cells, inhibiting cancer gene expression with low toxicity. This demonstrates potential for in-vivo nucleic acid drug delivery.
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Oncology
Background:
- Ewing sarcoma is a rare bone cancer with limited treatment options.
- Effective delivery of nucleic acid therapies like siRNA is crucial for targeted cancer treatment.
- Nanoparticles offer potential as carriers for nucleic acid drugs.
Purpose of the Study:
- To investigate the use of nanodiamonds (NDs) as a delivery vector for small interfering RNA (siRNA) in Ewing sarcoma cells.
- To evaluate the efficacy and safety of ND-siRNA complexes for potential in-vivo anticancer drug delivery.
Main Methods:
- siRNA was adsorbed onto nanodiamonds coated with a cationic polymer.
- Nanodiamond uptake by Ewing sarcoma cells was confirmed using their intrinsic fluorescence.
- Cell toxicity of the coated nanodiamonds was assessed.
- Inhibition of EWS/Fli-1 gene expression was measured at both mRNA and protein levels.
Main Results:
- Nanodiamonds successfully delivered siRNA into Ewing sarcoma cells.
- The nanodiamond-siRNA complexes exhibited low cytotoxicity.
- Specific inhibition of EWS/Fli-1 gene expression was observed at the mRNA and protein levels.
- Effective delivery was achieved in a serum-containing medium, relevant for in-vivo applications.
Conclusions:
- Cationic polymer-coated nanodiamonds are effective and safe vectors for siRNA delivery into Ewing sarcoma cells.
- ND-mediated siRNA delivery shows promise for targeted gene silencing in Ewing sarcoma treatment.
- This approach holds potential for future in-vivo nucleic acid-based cancer therapy.
